Nurix Therapeutics, Inc.

1. 01

   Fell 38.2% on 4 Nov 2026

   The 4 Nov 2026 decline of 38.2% was 16.1× its average daily move of 2.4% over the past year, and its largest one-day decline in a record that begins 26 Oct 2021.

   Daily closes, split-adjusted · as of 4 Nov 2026

2. 02

   Ahead of SPY, in line with its sector fund XLV over 1 year

   1 month: −29.4% (SPY −1.6%, XLV +13.5%). 3 months: −36.5% (SPY −0.4%, XLV +15.5%). 1 year: +30.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: NRIX, SPY and XLV · as of 4 Nov 2026

3. 03

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $15.95 was 35.5% below its 50-day average ($24.73) and 21.2% below its 200-day average ($20.23). It has closed below the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 1 Dec 2025, 233 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   Volume 8.1× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 19.6M shares was 8.1× the average of the 30 sessions before it (2.4M), as the price fell 38.2%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

5. 05

   9.2 days to cover short interest

   20.6M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 109.2M shares outstanding; covering them would take 9.2 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

At the 4 Nov 2026 close